MEDIA_REFRESH_DATA_PRESS_RELEASE
Media
U.S. News Room
Press Releases
Fri Dec 20 00:00:00 GMT-05:00 2019
ENHERTU® Approved in the U.S. for HER2 Positive Unresectable or Metastatic Breast Cancer Following Two or More Prior Anti-HER2-Based Regimens
Download
Wed Dec 11 00:00:00 GMT-05:00 2019
DS-8201 ([Fam-] Trastuzumab Deruxtecan) Achieved A Tumor Response Rate of 60.9% in Pivotal Phase 2 HER2 Positive Metastatic Breast Cancer Trial
Download
Tue Nov 19 00:00:00 GMT-05:00 2019
Positive Pivotal Data for Daiichi Sankyo’s DS-8201 ([Fam]-Trastuzumab Deruxtecan) in Patients with HER2 Positive Metastatic Breast Cancer to be Presented at SABCS
Download
Wed Nov 06 00:00:00 GMT-05:00 2019
Daiichi Sankyo Data at ASH Showcases Scientific and Clinical Advancements Across AML/Blood Cancer Portfolio
Download
Mon Nov 04 00:00:00 GMT-05:00 2019
Daiichi Sankyo Files Declaratory Judgement Action Related to its Proprietary Antibody Drug Conjugate Technology
Download
Thu Oct 31 00:00:00 GMT-05:00 2019
Daiichi Sankyo Initiates Clinical Trial with its 4th DXd Antibody Drug Conjugate, DS-7300, in Collaboration with Sarah Cannon Research Institute
Download
Thu Oct 17 00:00:00 GMT-05:00 2019
[Fam-] Trastuzumab Deruxtecan (DS-8201) Granted FDA Priority Review for Treatment of Patients with HER2 Positive Metastatic Breast Cancer
Download
Tue Sep 10 00:00:00 GMT-05:00 2019
Updated Clinical Results and New Biomarker Analyses Presented for Daiichi Sankyo’s DS-1062 in Patients with Advanced NSCLC at 2019 World Conference on Lung Cancer
Download
Tue Sep 10 00:00:00 GMT-05:00 2019
Updated Phase 1 Data for Daiichi Sankyo’s U3-1402 in Patients with EGFR Mutated NSCLC Presented at 2019 World Conference on Lung Cancer
Download